medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2018, Número 1

<< Anterior Siguiente >>

Residente 2018; 13 (1)


Artritis reumatoide y riesgo de fracturas osteoporóticas

Vizcaíno-Cortés ZG, Enríquez-Luna A, Esparza-Guerrero Y, Farías-Cuevas KP, Reyes-Reyes HA, Ramírez-Villafaña M, Castro-Jiménez A, Morales-Lira RI, Sánchez-Flores SE, Díaz-Pérez SA, González-López LC, Saldaña-Cruz AM

Idioma: Español
Referencias bibliográficas: 37
Paginas: 4-11
Archivo PDF: 247.83 Kb.


RESUMEN

La artritis reumatoide (AR) es una enfermedad autoinmune crónica, de etiología multifactorial con presencia de diferentes autoanticuerpos, caracterizada por inflamación poliarticular simétrica de más de tres grupos de articulaciones, sean éstas pequeñas o grandes, causa destrucción en el cartílago articular con incremento de riesgo de osteoporosis y fracturas osteoporóticas. La osteoporosis es una disminución de la masa ósea con aumento de la resorción ósea y disminución de la formación que conlleva a la fragilidad de la microarquitectura del hueso. Las fracturas osteoporóticas son 1.5 veces más comunes en pacientes con AR en comparación con controles sin la enfermedad. Su patogénesis es multifactorial con factores genéticos y epidemiológicos relacionados con la enfermedad y tratamientos, principalmente el uso indiscriminado de glucocorticoides, entre otros. Con relación a fracturas vertebrales, éstas se observan de dos a tres veces más que en población general. Esta revisión aborda los aspectos epidemiológicos, el diagnóstico y el tratamiento de fracturas osteoporóticas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365 (23): 2205-2219.

  2. Kim SY, Schneeweiss S, Liu J, Solomon DH. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res. 2012; 27 (4): 789-796.

  3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376 (9746): 1094-1108.

  4. Gonzalez-Lopez L, Rocha-Muñoz AD, Ponce-Guarneros M, Flores-Chavez A, Salazar-Paramo M, Nava A et al. Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis. J Immunol Res. 2014; 2014: 536050.

  5. Mota LM, Cruz BA, Brenola CV, Pereira IA, Rezende-Fronza LS, Bertolo MB et al. Guidelines for the diagnosis of rheumatoid arthritis. Rev Bras Reumatol. 2013; 53(2): 141-157.

  6. Ruiz A, Álvaro J, Sánchez J. Manual SER de las enfermedades reumáticas. 3ª ed. Madrid, España: Editorial Médica Panamericana; 2002. pp. 257-285.

  7. Dörner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol. 2004; 16 (3): 246-253.

  8. Díaz-Toscano ML, Olivas-Flores EM, Zavaleta-Muñiz SA, Gamez-Nava JI, Cardona-Muñoz EG, Ponce-Guarneros M et al. Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing. Biomed Res Int. 2014; 2014: 198198.

  9. Acevedo-Vásquez EM. Some aspects of rheumatoid arthritis in Peru. Rev Soc Peru Med Interna. 2012; 25 (1): 31-37.

  10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31 (3): 315-324.

  11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62 (9): 2569-2581.

  12. Alcaraz-Lopez MF, Gonzalez-Lopez L, Aguilar-Chavez L, Lopez-Olivo MA, Loaiza-Cardenas C, Gamez-Nava JI. Performance of albrand index for identifying low bone density in rheumatoid arthritis. Journal of Rheumatology. 2006; 33 (2): 408-409.

  13. Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford). 2014; 53 (10): 1759-1766.

  14. Llorente I, Merino L, Ortiz AM, Escolano E, González-Ortega S, García-Vicuña R et al. Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. Rheumatol Int. 2017; 37 (5): 799-806.

  15. Wysham KD, Shoback DM, Imboden JB Jr, Katz PP. Association of high anti-cyclic citrullinated peptide seropositivity and lean mass index with low bone mineral density in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2017 Nov 5. doi: 10.1002/acr.23440. [Epub ahead of print]

  16. Heidari B, Hassanjani-Roushan MR. Rheumatoid arthritis and osteoporosis. Caspian J Intern Med. 2012; 3 (3): 445-446.

  17. Ferrer A, Estrada MD, Borràs A, Espallargues M. Bone densitometry measurement and osteoporosis monitoring guide for the assessment of risk fracture. Med Clin (Barc). 2009; 132 (11): 428-436.

  18. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001; 12 (5): 417-427.

  19. Warriner AH, Patkar NM, Curtis JR, Delzell E, Gary L, Kilgore M et al. Which fractures are most attributable to osteoporosis? J Clin Epidemiol. 2011; 64 (1): 46-53.

  20. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17 (12): 1726-1733.

  21. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997; 7 (5): 407-413.

  22. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003; 18 (11): 1947-1954.

  23. Johnell O, Gullberg B, Allander E, Kanis JA; MEDOS Study Group. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int. 1992; 2 (6): 298-302.

  24. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005; 16 Suppl 2: S3-S7.

  25. Cooper C, O’Neill T, Silman A. The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone. 1993; 14 Suppl 1: S89-S97.

  26. El Maghraoui A, Rezqi A, El Mrahi S, Sadni S, Ghozlani I, Mounach A. Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women. BMC Endocr Disord. 2014; 14: 93.

  27. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15 (4): 721-739.

  28. Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1991; 115 (11): 837-842.

  29. Vogt TM, Ross PD, Palermo L, Musliner T, Genant HK, Black D et al. Vertebral fracture prevalence among women screened for the Fracture Intervention Trial and a simple clinical tool to screen for undiagnosed vertebral fractures. Fracture Intervention Trial Research Group. Mayo Clin Proc. 2000; 75 (9): 888-896.

  30. Duboeuf F, Hans D, Schott AM, Kotzki PO, Favier F, Marcelli C et al. Different morphometric and densitometric parameters predict cervical and trochanteric hip fracture: the EPIDOS Study. J Bone Miner Res. 1997; 12 (11): 1895-1902.

  31. Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F. Development and use of FRAX in osteoporosis. Osteoporos Int. 2010; 21 Suppl 2: S407-S413.

  32. Kostoglou-Athanassiou I, Athanassiou P, Lyraki A, Raftakis I, Antoniadis C. Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab. 2012; 3 (6): 181-187.

  33. Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017; 166 (11): 818-839.

  34. Nikander R, Sievänen H, Heinonen A, Daly RM, Uusi-Rasi K, Kannus P. Targeted exercise against osteoporosis: A systematic review and meta-analysis for optimising bone strength throughout life. BMC Med. 2010; 8: 47.

  35. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014; 25 (10): 2359-2381.

  36. Silverman SL1, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum. 2007; 37 (1): 1-12.

  37. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012; 23 (11): 576-581.




2020     |     www.medigraphic.com